Neurometrix Inc (NURO) 1.51 $NURO
NeuroMetrix Announces Issuance of Patent for DPNCheck Core Technology in China
BusinessWire - 1 hr 18 mins ago
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the State Intellectual Property Office of the People's Republic of China has issued Chinese Patent No. ZL20118055305.7 for the core technology underlying the Company's DPNCheck(R) device, which is a point-of-care test for peripheral neuropathies such as diabetic peripheral neuropathy (DPN). The patent claims cover the novel integrated design of the device that enables accurate and rapid measurement of sural nerve conduction, which is a standard neuropathy biomarker. Additional claims cover the automation algorithms and consumable biosensors.
NURO: 1.51 (+0.10)
NeuroMetrix Launches New Website to Support Growth of Quell Wearable Pain Relief Technology
BusinessWire - Tue Aug 30, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced the launch of a new website to promote Quell(R), the company's rapidly growing pain relief brand.
NURO: 1.51 (+0.10)
NeuroMetrix Announces That Quell Will Be Featured in the Target Open House
BusinessWire - Thu Aug 25, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) will be featured in the Target Open House in San Francisco.
NURO: 1.51 (+0.10)
NeuroMetrix Commentary on Strategic and Business Partnerships for Quell Wearable Pain Relief Technology
BusinessWire - Tue Aug 16, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today provided commentary on its Quell(R) partnership strategy.
NURO: 1.51 (+0.10)
NeuroMetrix To Present Quell Wearable Pain Technology at National Association of Chain Drug Stores Total Store Expo
BusinessWire - Wed Aug 03, 8:10AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that the company, in partnership with Advantage Healthcare, will explore Quell(R) retail expansion plans with executives from key national and regional drug chains and mass merchandisers at the NCADS Total Store Expo taking place in Boston from August 6 to 9.
NURO: 1.51 (+0.10)
NeuroMetrix Reports that the Quell Health Cloud Has Collected Over 1 Million Hours of Quell Therapy and Health Data
BusinessWire - Tue Aug 02, 9:22AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) announced a major milestone with over 1 million hours of Quell(R) therapy and health data uploaded to the Quell Health Cloud as of August 1, 2016. Quell is a wearable therapeutic technology that provides drug-free relief from chronic pain and is available without a prescription. The device communicates with a smartphone app that provides objective feedback to the user about their therapy utilization, sleep characteristics and activity levels. This data is securely backed up to the Quell Health Cloud. Novel insights from an analysis of this data include:
NURO: 1.51 (+0.10)
NeuroMetrix Reports Recent Media Coverage for Quell
BusinessWire - Thu Jul 28, 1:11PM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today reported continued strong media attention focusing on the company's innovative Quell(R) Wearable Pain Relief Technology(TM). Highlights include:
NURO: 1.51 (+0.10)
NeuroMetrix Submits CE Mark Application for Quell Wearable Pain Relief Device
BusinessWire - Wed Jun 22, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that a CE (Conformite Europeenne) Technical File Application for Quell(R) has been submitted to TA deg V SA deg D Product Service GmbH, which is one of the Notified Bodies responsible for reviewing and approving new products. This regulatory filing seeks QuellCE certification in the European Union as a class IIa medical device, as defined by the Medical Device Directive (93/42/EEC). CE certification or "CE Marking" will allow Quellto be marketed directly to consumers within the European Union.
NURO: 1.51 (+0.10)
NeuroMetrix Showcases Quell Technology at the Western Foot & Ankle Conference
BusinessWire - Tue Jun 21, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured at the Western Foot & Ankle Conference to be held June 23-26 in Anaheim, CA.
NURO: 1.51 (+0.10)
NeuroMetrix Announces Quell Distribution in Canada
BusinessWire - Tue Jun 14, 1:26PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) Wearable Pain Relief Technology(TM) is available in Canada via Amazon Canada.
NURO: 1.51 (+0.10)
NeuroMetrix Reports Executive Stock Transactions during May 2016
BusinessWire - Fri Jun 10, 10:31AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) which developed and markets Quell(R) Wearable Pain Relief Technology(TM), reported purchases during May 2016 of the company's common stock by its Chief Executive Officer, Dr. Shai N. Gozani; its Chief Financial Officer, Thomas T. Higgins; and its SVP and General Manager, Consumer, Frank McGillin. Details of these transactions may be found on the U.S. Securities and Exchange Commission's EDGAR website at the following links:
NURO: 1.51 (+0.10)
NeuroMetrix Showcases Quell Technology at SLEEP 2016, the 30th Anniversary Meeting of the Associated Professional Sleep Societies
BusinessWire - Thu Jun 09, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured at SLEEP 2016, which is a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. The meeting takes place June 11-15 in Denver, CO.
NURO: 1.51 (+0.10)
NeuroMetrix Closes $21.3 Million At-The-Market Private Placement of Preferred Stock and Warrants and Redeems $13.8 Million of Outstanding Preferred Stock
BusinessWire - Wed Jun 08, 3:27PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 21,300 shares of Series D convertible preferred stock at a price of $1,000 per share, and warrants to purchase an aggregate of approximately 11.8 million shares of common stock at an exercise price of $1.69 per share. The convertible preferred stock is convertible into 11.8 million shares of common stock at a conversion price of $1.805 per share, subject to certain ownership limitations.
NURO: 1.51 (+0.10)
NeuroMetrix Celebrates 20 Year Anniversary
BusinessWire - Mon Jun 06, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it is celebrating its twenty year anniversary.
NURO: 1.51 (+0.10)
NeuroMetrix Announces $21.3 Million at the Market Private Placement of Preferred Stock and Warrants
BusinessWire - Thu Jun 02, 3:19PM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 21,300 shares of Series C convertible preferred stock at a price of $1,000 per share and warrants to purchase an aggregate of approximately 11.8 million shares of common stock at an exercise price of $1.69 per share. The Company expects to receive gross proceeds from the offering of $21.3 million and it is expected that approximately $13.8 million of the proceeds of the offering will be used to redeem 13,800 shares of Series C convertible preferred stock held by the healthcare dedicated institutional investor and the balance of the proceeds will be used for general working capital purposes.
NURO: 1.51 (+0.10)
NeuroMetrix Announces Availability of Quell in Approximately 1,000 Chain Drug Stores
BusinessWire - Thu Jun 02, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) will be available, beginning in June 2016, in approximately 1,000 chain drug stores as part of a retail test with the two largest US drug retailers.
NURO: 1.51 (+0.10)
NeuroMetrix to Present at the LD Micro Invitational Conference on June 7, 2016
BusinessWire - Tue May 31, 10:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on the Company's business activities including the Quell(R) Wearable Pain Relief device.
NURO: 1.51 (+0.10)
NeuroMetrix Reports the Launch of the Quell(R) Health Cloud for Android
BusinessWire - Thu May 26, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), announced today the launch of the Quell Health Cloud for Android The updated Android app allows consumers to set up accounts on the Quell Health Cloud where their data is automatically backed-up to secure storage. This eliminates consumer worry about losing their therapy or sleep data, and allows them to review their data on multiple mobile devices. With the updated launch users of both the Android and iOS apps can tap into the Health Cloud capabilities.
NURO: 1.51 (+0.10)
NeuroMetrix Announces Frank McGillin, SVP and General Manager, Consumer to participate in a Digital Health Summer Summit Panel at BIO 2016
BusinessWire - Wed May 18, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin, Senior Vice President and General Manager, Consumer will participate in a panel discussion entitled "The Rise of Enterprise & Condition-Specific Wearables" during the Fifth Annual Digital Health Summer Summit. Digital Health is co-located with the 2016 Bio International Convention at the Moscone Center in San Francisco and the panel discussion will be held on Tuesday, June 7 at 11:15am (Pacific).
NURO: 1.51 (+0.10)
NeuroMetrix Announces Availability of Quell at Brookstone.com
BusinessWire - Mon May 16, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Quell(R) is now available at Brookstone.com.
NURO: 1.51 (+0.10)
NeuroMetrix Announces Issuance of Patent for DPNCheck Core Technology in China
BusinessWire - 1 hr 18 mins ago
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the State Intellectual Property Office of the People's Republic of China has issued Chinese Patent No. ZL20118055305.7 for the core technology underlying the Company's DPNCheck(R) device, which is a point-of-care test for peripheral neuropathies such as diabetic peripheral neuropathy (DPN). The patent claims cover the novel integrated design of the device that enables accurate and rapid measurement of sural nerve conduction, which is a standard neuropathy biomarker. Additional claims cover the automation algorithms and consumable biosensors.
NURO: 1.51 (+0.10)
NeuroMetrix Launches New Website to Support Growth of Quell Wearable Pain Relief Technology
BusinessWire - Tue Aug 30, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced the launch of a new website to promote Quell(R), the company's rapidly growing pain relief brand.
NURO: 1.51 (+0.10)
NeuroMetrix Announces That Quell Will Be Featured in the Target Open House
BusinessWire - Thu Aug 25, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) will be featured in the Target Open House in San Francisco.
NURO: 1.51 (+0.10)
NeuroMetrix Commentary on Strategic and Business Partnerships for Quell Wearable Pain Relief Technology
BusinessWire - Tue Aug 16, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today provided commentary on its Quell(R) partnership strategy.
NURO: 1.51 (+0.10)
NeuroMetrix To Present Quell Wearable Pain Technology at National Association of Chain Drug Stores Total Store Expo
BusinessWire - Wed Aug 03, 8:10AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that the company, in partnership with Advantage Healthcare, will explore Quell(R) retail expansion plans with executives from key national and regional drug chains and mass merchandisers at the NCADS Total Store Expo taking place in Boston from August 6 to 9.
NURO: 1.51 (+0.10)
NeuroMetrix Reports that the Quell Health Cloud Has Collected Over 1 Million Hours of Quell Therapy and Health Data
BusinessWire - Tue Aug 02, 9:22AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) announced a major milestone with over 1 million hours of Quell(R) therapy and health data uploaded to the Quell Health Cloud as of August 1, 2016. Quell is a wearable therapeutic technology that provides drug-free relief from chronic pain and is available without a prescription. The device communicates with a smartphone app that provides objective feedback to the user about their therapy utilization, sleep characteristics and activity levels. This data is securely backed up to the Quell Health Cloud. Novel insights from an analysis of this data include:
NURO: 1.51 (+0.10)
NeuroMetrix Reports Recent Media Coverage for Quell
BusinessWire - Thu Jul 28, 1:11PM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today reported continued strong media attention focusing on the company's innovative Quell(R) Wearable Pain Relief Technology(TM). Highlights include:
NURO: 1.51 (+0.10)
NeuroMetrix Submits CE Mark Application for Quell Wearable Pain Relief Device
BusinessWire - Wed Jun 22, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that a CE (Conformite Europeenne) Technical File Application for Quell(R) has been submitted to TA deg V SA deg D Product Service GmbH, which is one of the Notified Bodies responsible for reviewing and approving new products. This regulatory filing seeks QuellCE certification in the European Union as a class IIa medical device, as defined by the Medical Device Directive (93/42/EEC). CE certification or "CE Marking" will allow Quellto be marketed directly to consumers within the European Union.
NURO: 1.51 (+0.10)
NeuroMetrix Showcases Quell Technology at the Western Foot & Ankle Conference
BusinessWire - Tue Jun 21, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured at the Western Foot & Ankle Conference to be held June 23-26 in Anaheim, CA.
NURO: 1.51 (+0.10)
NeuroMetrix Announces Quell Distribution in Canada
BusinessWire - Tue Jun 14, 1:26PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) Wearable Pain Relief Technology(TM) is available in Canada via Amazon Canada.
NURO: 1.51 (+0.10)
NeuroMetrix Reports Executive Stock Transactions during May 2016
BusinessWire - Fri Jun 10, 10:31AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) which developed and markets Quell(R) Wearable Pain Relief Technology(TM), reported purchases during May 2016 of the company's common stock by its Chief Executive Officer, Dr. Shai N. Gozani; its Chief Financial Officer, Thomas T. Higgins; and its SVP and General Manager, Consumer, Frank McGillin. Details of these transactions may be found on the U.S. Securities and Exchange Commission's EDGAR website at the following links:
NURO: 1.51 (+0.10)
NeuroMetrix Showcases Quell Technology at SLEEP 2016, the 30th Anniversary Meeting of the Associated Professional Sleep Societies
BusinessWire - Thu Jun 09, 6:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell(R) Wearable Pain Relief Technology(TM) will be featured at SLEEP 2016, which is a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. The meeting takes place June 11-15 in Denver, CO.
NURO: 1.51 (+0.10)
NeuroMetrix Closes $21.3 Million At-The-Market Private Placement of Preferred Stock and Warrants and Redeems $13.8 Million of Outstanding Preferred Stock
BusinessWire - Wed Jun 08, 3:27PM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants. The Company sold to a healthcare dedicated institutional investor 21,300 shares of Series D convertible preferred stock at a price of $1,000 per share, and warrants to purchase an aggregate of approximately 11.8 million shares of common stock at an exercise price of $1.69 per share. The convertible preferred stock is convertible into 11.8 million shares of common stock at a conversion price of $1.805 per share, subject to certain ownership limitations.
NURO: 1.51 (+0.10)
NeuroMetrix Celebrates 20 Year Anniversary
BusinessWire - Mon Jun 06, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it is celebrating its twenty year anniversary.
NURO: 1.51 (+0.10)
NeuroMetrix Announces $21.3 Million at the Market Private Placement of Preferred Stock and Warrants
BusinessWire - Thu Jun 02, 3:19PM CDT
NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 21,300 shares of Series C convertible preferred stock at a price of $1,000 per share and warrants to purchase an aggregate of approximately 11.8 million shares of common stock at an exercise price of $1.69 per share. The Company expects to receive gross proceeds from the offering of $21.3 million and it is expected that approximately $13.8 million of the proceeds of the offering will be used to redeem 13,800 shares of Series C convertible preferred stock held by the healthcare dedicated institutional investor and the balance of the proceeds will be used for general working capital purposes.
NURO: 1.51 (+0.10)
NeuroMetrix Announces Availability of Quell in Approximately 1,000 Chain Drug Stores
BusinessWire - Thu Jun 02, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell(R) will be available, beginning in June 2016, in approximately 1,000 chain drug stores as part of a retail test with the two largest US drug retailers.
NURO: 1.51 (+0.10)
NeuroMetrix to Present at the LD Micro Invitational Conference on June 7, 2016
BusinessWire - Tue May 31, 10:00AM CDT
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the upcoming LD Micro Invitational at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr. Gozani intends to provide an update on the Company's business activities including the Quell(R) Wearable Pain Relief device.
NURO: 1.51 (+0.10)
NeuroMetrix Reports the Launch of the Quell(R) Health Cloud for Android
BusinessWire - Thu May 26, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO), announced today the launch of the Quell Health Cloud for Android The updated Android app allows consumers to set up accounts on the Quell Health Cloud where their data is automatically backed-up to secure storage. This eliminates consumer worry about losing their therapy or sleep data, and allows them to review their data on multiple mobile devices. With the updated launch users of both the Android and iOS apps can tap into the Health Cloud capabilities.
NURO: 1.51 (+0.10)
NeuroMetrix Announces Frank McGillin, SVP and General Manager, Consumer to participate in a Digital Health Summer Summit Panel at BIO 2016
BusinessWire - Wed May 18, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin, Senior Vice President and General Manager, Consumer will participate in a panel discussion entitled "The Rise of Enterprise & Condition-Specific Wearables" during the Fifth Annual Digital Health Summer Summit. Digital Health is co-located with the 2016 Bio International Convention at the Moscone Center in San Francisco and the panel discussion will be held on Tuesday, June 7 at 11:15am (Pacific).
NURO: 1.51 (+0.10)
NeuroMetrix Announces Availability of Quell at Brookstone.com
BusinessWire - Mon May 16, 6:00AM CDT
NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Quell(R) is now available at Brookstone.com.
NURO: 1.51 (+0.10)
